John M, Crean T I, Calderwood S B, Ryan E T
Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
Infect Immun. 2000 Mar;68(3):1171-5. doi: 10.1128/IAI.68.3.1171-1175.2000.
The optimal promoter for in vivo expression of heterologous antigens by live, attenuated vaccine vector strains of Vibrio cholerae is unclear; in vitro analyses of promoter activity may not accurately predict expression of antigens in vivo. We therefore introduced plasmids expressing the B subunit of cholera toxin (CtxB) under the control of a number of promoters into V. cholerae vaccine strain Peru2. We evaluated the tac promoter, which is constitutively expressed in V. cholerae, as well as the in vivo-induced V. cholerae heat shock htpG promoter and the in vivo-induced V. cholerae iron-regulated irgA promoter. The functionality of all promoters was confirmed in vitro. In vitro antigenic expression was highest in vaccine strains expressing CtxB under the control of the tac promoter (2 to 5 microgram/ml/unit of optical density at 600 nm [OD(600)]) and, under low-iron conditions, in strains containing the irgA promoter (5 microgram/ml/OD(600)). We orally inoculated mice with the various vaccine strains and used anti-CtxB immune responses as a marker for in vivo expression of CtxB. The vaccine strain expressing CtxB under the control of the tac promoter elicited the most prominent specific anti-CtxB responses in vivo (serum immunoglobulin G [IgG], P </= 0.05; serum IgA, P </= 0.05; stool IgA, P </= 0.05; bile IgA, P </= 0.05), despite the finding that the tac and irgA promoters expressed equivalent amounts of CtxB in vitro. Vibriocidal antibody titers were equivalent in all groups of animals. Our results indicate that in vitro assessment of antigen expression by vaccine and vector strains of V. cholerae may correlate poorly with immune responses in vivo and that of the promoters examined, the tac promoter may be best suited for expression from plasmids of at least certain heterologous antigens in such strains.
霍乱弧菌减毒活疫苗载体菌株在体内表达异源抗原的最佳启动子尚不清楚;对启动子活性的体外分析可能无法准确预测抗原在体内的表达情况。因此,我们将在多种启动子控制下表达霍乱毒素B亚单位(CtxB)的质粒导入霍乱弧菌疫苗株Peru2。我们评估了在霍乱弧菌中组成性表达的tac启动子,以及体内诱导的霍乱弧菌热休克htpG启动子和体内诱导的霍乱弧菌铁调节irgA启动子。所有启动子的功能均在体外得到证实。在tac启动子控制下表达CtxB的疫苗株中,体外抗原表达最高(2至5微克/毫升/600纳米光密度单位[OD(600)]),在低铁条件下,含有irgA启动子的菌株中表达量最高(5微克/毫升/OD(600))。我们用各种疫苗株口服接种小鼠,并将抗CtxB免疫反应作为体内CtxB表达的标志物。尽管发现在体外tac和irgA启动子表达的CtxB量相当,但在tac启动子控制下表达CtxB的疫苗株在体内引发了最显著的特异性抗CtxB反应(血清免疫球蛋白G[IgG],P≤0.05;血清IgA,P≤0.05;粪便IgA,P≤0.05;胆汁IgA,P≤0.05)。所有动物组的杀弧菌抗体滴度相当。我们的结果表明,霍乱弧菌疫苗和载体菌株抗原表达的体外评估可能与体内免疫反应相关性较差,在所检测的启动子中,tac启动子可能最适合在这类菌株中从质粒表达至少某些异源抗原。